Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,850,720
  • Shares Outstanding, K 2,532,896
  • Annual Sales, $ 22,090 M
  • Annual Income, $ 2,155 M
  • 60-Month Beta 0.52
  • Price/Sales 4.87
  • Price/Cash Flow 11.42
  • Price/Book 7.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.41
  • Number of Estimates 3
  • High Estimate 0.45
  • Low Estimate 0.35
  • Prior Year 0.48
  • Growth Rate Est. (year over year) -14.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.14 +6.80%
on 02/21/19
43.06 -0.44%
on 03/19/19
+2.41 (+5.96%)
since 02/19/19
3-Month
35.30 +21.44%
on 01/28/19
43.06 -0.44%
on 03/19/19
+4.90 (+12.90%)
since 12/19/18
52-Week
34.11 +25.68%
on 03/23/18
43.06 -0.44%
on 03/19/19
+8.30 (+24.01%)
since 03/19/18

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

AVGO : 299.31 (+1.86%)
AZN : 42.87 (+0.68%)
MRK : 81.91 (+0.69%)
ADBE : 260.42 (+1.03%)
ROST : 91.72 (+0.65%)
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

CELG : 89.07 (+1.23%)
AZN : 42.87 (+0.68%)
KMDA : 5.89 (-0.42%)
PHAS : 6.20 (-0.48%)
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

AZN : 42.87 (+0.68%)
MRK : 81.91 (+0.69%)
RHHBY : 33.6950 (-0.49%)
BMY : 49.60 (-0.52%)
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

AZN : 42.87 (+0.68%)
NVS : 92.99 (-0.19%)
GSK : 40.45 (-0.10%)
BMY : 49.60 (-0.52%)
Top Research Reports for Merck, Adobe & Broadcom

Top Research Reports for Merck, Adobe & Broadcom

AVGO : 299.31 (+1.86%)
AZN : 42.87 (+0.68%)
MRK : 81.91 (+0.69%)
ROST : 91.72 (+0.65%)
ADBE : 260.42 (+1.03%)
PSA : 217.48 (-0.13%)
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

AZN : 42.87 (+0.68%)
INO : 3.60 (+2.27%)
RHHBY : 33.6950 (-0.49%)
REGN : 406.99 (-0.15%)
First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

--FARXIGA reduced hospitalization for heart failure regardless of ejection fraction status

AZN : 42.87 (+0.68%)
AstraZeneca Up This Year on New Drugs & Pipeline Progress

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

BAYRY : 19.6700 (+2.50%)
CELG : 89.07 (+1.23%)
AZN : 42.87 (+0.68%)
MRK : 81.91 (+0.69%)
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag

AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.

BAYRY : 19.6700 (+2.50%)
AVEO : 0.61 (unch)
CELG : 89.07 (+1.23%)
AZN : 42.87 (+0.68%)
Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

BAYRY : 19.6700 (+2.50%)
AZN : 42.87 (+0.68%)
MRK : 81.91 (+0.69%)
BMY : 49.60 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 43.22
1st Resistance Point 43.04
Last Price 42.87
1st Support Level 42.71
2nd Support Level 42.56

See More

52-Week High 43.06
Last Price 42.87
Fibonacci 61.8% 39.64
Fibonacci 50% 38.58
Fibonacci 38.2% 37.53
52-Week Low 34.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar